Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protease, serine, 1 (trypsin 1) | References | |
Homo sapiens | chymase 1, mast cell | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 3 | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 2 (trypsin 2) | References | |
Homo sapiens | cathepsin G | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 3 | 261 aa | 234 aa | 25.2 % |
Brugia malayi | Trypsin family protein | chymase 1, mast cell | 247 aa | 295 aa | 24.1 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 2 (trypsin 2) | 247 aa | 240 aa | 25.8 % |
Schistosoma mansoni | cercarial elastase (S01 family) | cathepsin G | 255 aa | 209 aa | 25.8 % |
Brugia malayi | Trypsin family protein | protease, serine, 1 (trypsin 1) | 247 aa | 287 aa | 21.6 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 3 % | Oral bioavailability in rat | ChEMBL. | 17361995 |
IC50 (binding) | = 29 nM | Inhibition of human skin chymase | ChEMBL. | 17361995 |
IC50 (binding) | = 29 nM | Inhibition of human skin chymase | ChEMBL. | 17361995 |
IC50 (binding) | = 12 uM | Inhibition of human trypsin | ChEMBL. | 17361995 |
IC50 (binding) | = 12 uM | Inhibition of human trypsin | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human chymotrypsin at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human beta-tryptase at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human alpha-thrombin at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human factor Xa at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human factor VIIa at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human leukocyte elastase at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human factor Xa at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human factor VIIa at 100 uM | ChEMBL. | 17361995 |
Inhibition (binding) | < 50 % | Inhibition of human leukocyte elastase at 100 uM | ChEMBL. | 17361995 |
Ki (binding) | = 36 nM | Inhibition of human skin chymase | ChEMBL. | 17361995 |
Ki (binding) | = 36 nM | Inhibition of human skin chymase | ChEMBL. | 17361995 |
Ki (binding) | = 9500 nM | Inhibition of human neutrophil Cat G | ChEMBL. | 17361995 |
Ki (binding) | = 9500 nM | Inhibition of human neutrophil Cat G | ChEMBL. | 17361995 |
Ratio Ki (binding) | = 260 | Selectivity for chymase over Cat G | ChEMBL. | 17361995 |
t1/2 (ADMET) | = 1.8 hr | Half life in orally dosed rat | ChEMBL. | 17361995 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.